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CPR. The positive results of the ResQTrial, the 
most recently reported randomized trial com-
paring active compression–decompression CPR 
plus ITD with standard CPR, suggests there may 
be a synergistic effect between these two inter-
ventions that would explain the discordant find-
ings noted in the two meta-analyses. Although 
useful, meta-analyses are limited by methodo-
logic differences between trials. Since blinding 
of active compression–decompression CPR is not 
possible, the best scientific approach to answer 
the question regarding the relative contribution 
of each intervention toward improved survival 
with the device combination would be to con-
duct a large randomized study comparing active 
compression–decompression CPR with an active 
ITD and a sham ITD.
Tom P. Aufderheide, M.D.
Medical College of Wisconsin 
Milwaukee, WI
Alan Craig, M.S.
Toronto Emergency Medical Services 
Toronto, ON, Canada
Brian G. Leroux, Ph.D.
University of Washington 
Seattle, WA
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Cabrini L, Beccaria P, Landoni G, et al. Impact of impedance 
threshold device on cardiopulmonary resuscitation: a systematic 
review and meta-analysis of randomized controlled studies. Crit 
Care Med 2008;36:1625-32.
2. Lafuente-Lafuente C, Melero-Bascones M. Active chest com-
pression-decompression for cardiopulmonary resuscitation. Co-
chrane Database Syst Rev 2004;2:CD002751.
Table 1. Patient Population Stratified According to Time from Dispatch of Emergency Medical Services (EMS) Personnel 
to Placement of Impedance Threshold Device (ITD) and Time from Dispatch to Arrival of EMS Personnel.
Subgroup Sham ITD Active ITD Difference (%)*
no. of survivors to hospital discharge  
with modified Rankin score ≤3/total no. (%)†
Time from EMS dispatch to ITD placement — min
0 to 8 93/972 (9.6) 81/921 (8.8) −0.8
>8 to 16 137/2315 (5.9) 128/2337 (5.5) −0.4
>16 20/837 (2.4) 30/881 (3.4) 1.0
Not available 10/221 (4.5) 15/234 (6.4) 1.9
Time from EMS dispatch to EMS arrival — min
0 to 5 134/1834 (7.3) 124/1789 (6.9) −0.4
>5 to 10 120/2291 (5.2) 124/2348 (5.3) 0.04
>10 6/220 (2.7) 6/236 (2.5) −0.2
* The between-group differences were not significant.
† The modified Rankin scale is a validated scale that is commonly used to measure the performance of daily activities 
by people who have had a stroke. Scores range from 0 to 6, with higher numbers indicating greater disability.
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
To the Editor: On the basis of data obtained in 
the Adjuvant Zoledronic Acid to Reduce Recur-
rence (AZURE) trial (Current Controlled Trials 
number, ISRCTN79831382), Coleman et al. (Oct. 
13 issue)1 question the capacity of the amino-
bisphosphonate zoledronic acid to reduce the re-
currence of breast cancer in the adjuvant setting. 
This reduction was previously reported in the 
Austrian Breast and Colorectal Cancer Study 
Group (ABCSG-12) trial (ClinicalTrials.gov num-
ber, NCT00295646).2
A notable difference in the initial treatment 
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schedule of zoledronic acid in the ABCSG-12 
study (once every 6 months) and the AZURE 
study (once every 3 to 4 weeks) could account 
for this apparent discrepancy. It is known that 
the aminobisphosphonate-induced activation of 
Vγ9Vδ2 T cells, which have been proposed to be 
key mediators of the antitumor effects of amino-
bisphosphonates, is reduced with each subse-
quent administration of aminobisphosphonate. 
Therefore, the more frequent administration of 
zoledronic acid in the AZURE study might have 
induced a state of functional exhaustion in 
Vγ9Vδ2 T cells and impaired antitumor activity.3,4
Interestingly, in the AZURE study, patients 
were randomly assigned to treatment according 
to statin use or nonuse. Since statins inhibit 
Vγ9Vδ2 T-cell activation by preventing the amino-
bisphosphonate-induced accumulation of its ac-
tivating ligand, isopentenyl pyrophosphate, it is 
unfortunate that the authors provide no infor-
mation on differences in outcome according to 
statin use or nonuse, since this might have pro-
vided essential additional insight into the puta-
tive antitumor mechanism of aminobisphospho-
nate therapy.5
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The Authors Reply: We think it is unlikely that 
the apparent differences in outcome between the 
AZURE and ABCSG-12 studies were related to 
functional exhaustion of Vγ9Vδ2 T cells induced 
by the intensive regimen of zoledronic acid used 
in our trial. Such an explanation would not be 
consistent with the significant heterogeneity of 
treatment effects according to menopausal sta-
tus. In the AZURE trial, significant improvements 
in disease outcomes were seen in women more 
than 5 years after menopause, whereas in the 
ABCSG-12 trial, all women received ovarian-sup-
pression therapy to induce menopause; thus, the 
results from the two trials could be considered 
consistent.
The use of statins in 6% of the AZURE trial 
population did not modify the treatment effects 
observed with zoledronic acid. The hazard ratios 
for disease recurrence or death were 0.81 (95% 
confidence interval [CI], 0.43 to 1.51) in 198 pa-
tients who received statins and 1.01 (95% CI, 0.87 
to 1.17) in 3161 patients who did not receive 
statins. Similarly, in the patients who had under-
gone menopause more than 5 years earlier and 
who appeared to benefit from treatment with 
zoledronic acid, statin use did not influence the 
treatment effect (hazard ratio for disease recur-
rence or death with statin therapy, 0.65; 95% CI, 
0.30 to 1.39; and hazard ratio for disease recur-
rence or death without statin therapy, 0.80; 95% 
CI, 0.61 to 1.05).
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